This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The approval is supported by data from three pivotal clinical trials
The study met its primary endpoint with flying colors
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
